Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer
JCO Precis Oncol
.
2023 Mar:7:e2200483.
doi: 10.1200/PO.22.00483.
Authors
Natalie Reizine
1
,
Samantha Socco
2
,
Eric Weng
1
,
Uka Atueyi
3
,
Vikas Mehta
4
,
Akash Patnaik
5
Affiliations
1
Division of Hematology and Oncology, Department of Medicine, The University of Illinois at Chicago, Chicago, IL.
2
College of Pharmacy, The University of Illinois at Chicago, Chicago, IL.
3
Department of Radiology, The University of Illinois at Chicago, Chicago, IL.
4
Department of Pathology, The University of Illinois at Chicago, Chicago, IL.
5
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.
PMID:
36996374
DOI:
10.1200/PO.22.00483
No abstract available
MeSH terms
High-Throughput Nucleotide Sequencing
Humans
Immunohistochemistry
Male
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / genetics